Paul Schimmel Acquires 100,000 Shares of aTyr Pharma (NASDAQ:ATYR) Stock

Posted by Geri Gentry on May 30th, 2026

aTyr Pharma, Inc. (NASDAQ:ATYR – Get Free Report) Director Paul Schimmel bought 100,000 shares of the company’s stock in a transaction dated Wednesday, May 27th. The shares were purchased at an average price of $0.50 per share, with a total value of $50,000.00. Following the completion of the acquisition, the director owned 779,143 shares of the company’s stock, valued at $389,571.50. This trade represents a 14.72% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

aTyr Pharma Trading Up 11.3%

aTyr Pharma stock opened at $0.54 on Friday. The firm has a 50-day moving average of $0.74 and a 200-day moving average of $0.78. The firm has a market cap of $53.19 million, a P/E ratio of -0.74 and a beta of 0.66. aTyr Pharma, Inc. has a 1-year low of $0.40 and a 1-year high of $7.29.

aTyr Pharma (NASDAQ:ATYR – Get Free Report) last posted its earnings results on Friday, May 15th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. Research analysts forecast that aTyr Pharma, Inc. will post -0.66 earnings per share for the current fiscal year.

Institutional Trading of aTyr Pharma

Institutional investors and hedge funds have recently bought and sold shares of the stock. California State Teachers Retirement System purchased a new position in shares of aTyr Pharma during the second quarter valued at approximately $28,000. Main Street Financial Solutions LLC lifted its holdings in shares of aTyr Pharma by 7.0% during the second quarter. Main Street Financial Solutions LLC now owns 143,600 shares of the company’s stock valued at $728,000 after purchasing an additional 9,350 shares during the last quarter. Legal & General Group Plc purchased a new position in shares of aTyr Pharma during the second quarter valued at approximately $49,000. Raymond James Financial Inc. lifted its holdings in shares of aTyr Pharma by 79.3% during the second quarter. Raymond James Financial Inc. now owns 24,839 shares of the company’s stock valued at $126,000 after purchasing an additional 10,989 shares during the last quarter. Finally, Prudential Financial Inc. purchased a new position in shares of aTyr Pharma during the second quarter valued at approximately $63,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of aTyr Pharma from a “sell” rating to a “hold” rating in a report on Sunday, May 17th. Jefferies Financial Group restated a “buy” rating on shares of aTyr Pharma in a report on Friday, March 6th. Freedom Capital upgraded shares of aTyr Pharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of aTyr Pharma in a report on Friday, May 22nd. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $25.67.

Read Our Latest Report on aTyr Pharma

About aTyr Pharma

(Get Free Report)

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.